Arcus Biosciences, Inc.RCUSEarnings & Financial Report
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
RCUS Q4 FY2025 Key Financial Metrics
Revenue
$11.0M
Gross Profit
N/A
Operating Profit
$-114.0M
Net Profit
$-106.0M
Gross Margin
N/A
Operating Margin
-1036.4%
Net Margin
-963.6%
YoY Growth
-52.2%
EPS
$-0.88
Arcus Biosciences, Inc. Q4 FY2025 Financial Summary
Arcus Biosciences, Inc. reported revenue of $11.0M (down 52.2% YoY) for Q4 FY2025, with a net profit of $-106.0M (down 12.8% YoY) (-963.6% margin).
Key Financial Metrics
| Total Revenue | $11.0M |
|---|---|
| Net Profit | $-106.0M |
| Gross Margin | N/A |
| Operating Margin | -1036.4% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Arcus Biosciences, Inc. Q4 FY2025 revenue of $11.0M breaks down across 3 segments, led by Other at $5.0M (45.5% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $5.0M | 45.5% |
| Other Collaboration Revenue | $4.0M | 36.4% |
| Access Rights And Option Continuation Periods | $2.0M | 18.2% |
Arcus Biosciences, Inc. Revenue by Segment — Quarterly Trend
Arcus Biosciences, Inc. revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Other Collaboration Revenue) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $5.0M | — | — | — |
| Other Collaboration Revenue | $4.0M | $6.0M | $8.0M | $8.0M |
| Access Rights And Option Continuation Periods | $2.0M | — | — | — |
Arcus Biosciences, Inc. Annual Revenue by Year
Arcus Biosciences, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $33.0M).
Arcus Biosciences, Inc. Quarterly Revenue & Net Profit History
Arcus Biosciences, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $11.0M | -52.2% | $-106.0M | -963.6% |
| Q3 FY2025 | $6.0M | -14.3% | $-135.0M | -2250.0% |
| Q2 FY2025 | $8.0M | -27.3% | $0 | N/A |
| Q1 FY2025 | $8.0M | -20.0% | $-112.0M | -1400.0% |
| Q4 FY2024 | $23.0M | +146.9% | $-94.0M | -408.7% |
| Q3 FY2024 | $7.0M | -78.1% | $-92.0M | -1314.3% |
| Q2 FY2024 | $11.0M | -62.1% | $-93.0M | -845.5% |
| Q1 FY2024 | $10.0M | -60.0% | $-4.0M | -40.0% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.0M | $11.0M | $7.0M | $23.0M | $8.0M | $8.0M | $6.0M | $11.0M |
| YoY Growth | -60.0% | -62.1% | -78.1% | 146.9% | -20.0% | -27.3% | -14.3% | -52.2% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.29B | $1.19B | $1.25B | $1.15B | $1.16B | $1.07B | $974.0M | $1.14B |
| Liabilities | $586.0M | $551.0M | $687.0M | $665.0M | $625.0M | $526.0M | $538.0M | $508.0M |
| Equity | $707.0M | $635.0M | $565.0M | $485.0M | $531.0M | $549.0M | $436.0M | $631.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-2.0M | $-94.0M | $26.0M | $-100.0M | $-132.0M | $-133.0M | $-97.0M | $-120.0M |